Net profit of Themis Medicare declined 44.63% to Rs 7.37 crore in the quarter ended December 2023 as against Rs 13.31 crore during the previous quarter ended December 2022. Sales declined 7.06% to Rs 82.51 crore in the quarter ended December 2023 as against Rs 88.78 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales82.5188.78 -7 OPM %9.7717.20 - PBDT11.3120.17 -44 PBT8.2217.50 -53 NP7.3713.31 -45 Powered by Capital Market - Live News

Themis Medicare will hold a meeting of the Board of Directors of the Company on 10 February 2024.Powered by Capital Market - Live News

Themis Medicare announced the launch of a novel Opioid Injectable Analgesic REMIFENTANIL under its brand name REMITHEM�in the Indian market for use during induction of anesthesia, during immediate post operative period and in monitored anesthesia care. Remifentanil� was first approved in USA in 1996 and has wide clinical usage & acceptance around the world in major markets including USA, Europe, Japan and other countries and is also well published. Powered by Capital Market - Live News

Net profit of Themis Medicare declined 36.33% to Rs 11.32 crore in the quarter ended September 2023 as against Rs 17.78 crore during the previous quarter ended September 2022. Sales rose 15.14% to Rs 104.78 crore in the quarter ended September 2023 as against Rs 91.00 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales104.7891.00 15 OPM %11.8423.46 - PBDT17.0325.19 -32 PBT13.9622.63 -38 NP11.3217.78 -36 Powered by Capital Market - Live News

Themis Medicare will hold a meeting of the Board of Directors of the Company on 4 November 2023.Powered by Capital Market - Live News